Nurse Appreciation from the Survivor and Caregiver Audience
We asked patients, survivors, and caregivers to give their oncology nurses a shout out. Here's what they had to say.
In conjunction with National Nurses Week, held May 6 through 12, Oncology Nursing News and its sister publication, CURE, asked individuals to highlight some of the amazing oncology nurses who helped them through their cancer journey and beyond. Here is what some social media users had to say:
“Thank you for CARING for me, nurses! I’m sorry that I gave you a hard time.” — SS
“Thanks to all the oncology nurses at Moffitt Cancer Center who helped my husband have quality of life for 2 1/2 years, I never forgot their love and compassion toward their patients. It was like family.” — LM
“I had several oncology nurses [who] were amazing and made my treatments bearable. Love how they made everything seem so easy, normal, and routine, and made me feel safe. Many times, they would sit and talk with my husband and me about their families or we would laugh about things. They have no idea how much that helped.” — DD
“Thank you to all of my oncology nurses and staff that take great care of me every 6 weeks during my chemo. I appreciate you all more than you know. Love you all. You are our second family.” — KG
“(University of California, San Francisco) oncology nurses ROCK!! Caring, compassionate, knowledgeable — true angels!” – LY
“A thank you to all the oncology staff at JCMG Oncology and to the nursing staff at St. Mary’s in Jefferson City who cared for my wife and stayed by her side in the end. It meant so much to me to have them there and see their compassion for her and our grieving family.” — ED
“(Memorial Sloan Kettering Cancer Center) nurses are amazing. God bless them.” — JP.
“Thanks for being who you are and what you do!” — SR
Dual Checkpoint Inhibition Increases Response Rates, Adverse Effects in Melanoma
April 19th 2024Patients with high-risk resectable melanoma treated with ipilimumab plus nivolumab had increased response rates compared with anti-PD1 monotherapy, though it was also associated with increased immune-related adverse effects.
